Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries

Official record

Identifier

NCT07539844

Recruiting locations

countries

ArgentinaBrazilColombia

Interventions studied

Not provided in the official record

Lead sponsor

AbbVie

Target enrolment

1000 participants

Study type

OBSERVATIONAL

Phase

Not provided in the official record

Status

Recruiting

First posted

Apr 20, 2026

Last updated on the registry

Jul 31, 2026

Age

18 Years

Sex

FEMALE

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Surgical or biopsy samples (Formalin Fixed Paraffin Embedded \[FFPE\]) with tumoral High Grade Serous Ovarian Cancer (HGSOC) material allowing the sectioning of serial slides for all the analyses.
* Archival specimens should not be older than 5 years in order to control quality of the samples.
* Specimens containing a minimum of 100 viable tumor cells.

Exclusion Criteria:

* Surgical or biopsy samples (FFPE) with insufficient quantity or quality (sampled more than 5 years ago and/or with less 100 viable tumor cells per section).
* Tissue obtained following treatment with Mirvetuximab soravtansine or any other FRa targeted therapy.
* Tissue obtained through fine needle aspirations or liquid specimens, or ascites